CClinicalTrials.gg
RecruitingNCT06997809ENDALGOUpdated Sep 4, 2026

ENDometriosis: Evaluation of Detection and Need for ALGOlogic Care Before Surgery

An interventional study of pathway care in Endometriosis, Pain, sponsored by University Hospital, Limoges. Recruiting at 9 sites in France. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by University Hospital, Limoges · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Endometriosis surgery is required when medical treatment fails to release women from pain. However, complete surgery does not work every time to improve patients' symptoms. Algological care is one of the options to treat the pain before surgery and their related complications (neuropathy, sensitization, and catastrophism) that could be associated to nociceptive pain.

But not all patients could benefit from this pathway and no screening strategy does exist to detect these complications that could be treated prior to endometriosis surgery

02

Conditions studied

  • Endometriosis, Pain

Keywords

  • endometriosis, algologic care
  • pain, quality of life
03

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Maternal age from 18 up to 50 years old (50 non included).
  • Women affiliated to social coverage insurance
  • Women who understand French
  • Women who signed the written consent
  • Women with impaired quality of life (pain) linked to endometriosis
  • Women with formal radiological signs of endometriosis (MRI lesions more than 5 mm or endometrioma more than 20 mm on radiological examinations).
  • Surgical indication for resection of lesions by laparoscopy or robotic surgery for management of pain or impairment of quality of life
  • Patients requiring complete conservative or radical resections of all lesions
  • Indication of surgery validated within dedicated meeting for endometriosis.
  • Purpose of pain associated or not with infertility
  • Date of surgery fixed with sufficient time for algological treatment. Maximum delay of 4 months between randomization and surgery

Exclusion criteria

Exclusion criteria:

  • Women undergoing surgery for the purpose of infertility
  • Patient with previous surgery for removal of deep lesions of endometriosis or endometriotic cysts (history of exploratory laparoscopy accepted)
  • Patient with suspicious lesions on MRI or specialized ultrasound.
  • A patient who needs to be treated for another uterine pathology at the same time.
  • Pregnant women
  • Patient with a desire for pregnancy immediately and/or within one year after surgery
  • Women who refuse clinical examination (some algological tests couldn't be performed without clinical examination)
  • Patient who has already received algological treatment or who should receive it before surgery
  • Patient with previous other psychiatric disorders (depressive symptoms treated)
  • Women without rights
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
187 participants (estimated)

Study arms

  • No intervention
    Control

    Surgery without calculation of pain questionnaire scores

  • Experimental
    group with adapted support

    The calculation of pain questionnaire scores is carried out to direct or not the patient towards pain consultations before surgery. Only patients with at least one positive test benefit from an algology consultation before surgery.

    Other: pathway care

Interventions

  • Otherpathway care

    Group for whom the test results will be used to determine the management strategy. If one of the tests performed before randomization is positive an algological consultation before surgery will be performed with an adapted treatment. Then surgical treatment as planned. If all tests are negative, surgical treatment is performed. The dedicated algology consultation must be done with an experienced practitioner different from the one who will perform the surgery. A rapid algological treatment circuit must be put in place to maintain the surgery date set. Group without using the results of test for associated pain components. Standard surgical treatment as planned through dedicated staff on endometriosis treatment.

05

What researchers measure

Primary outcomes

  1. Evaluation of quality of life

    Quality of life is assessed by the EHP5 score translated in French and validated in endometriosis. The primary endpoint is the comparison of EHP5 scores between the 2 groups (intervention vs. standard treatment) at 1 year after surgery for complete removal of deep endometriosis

    Time frame: 1 year after surgery

Secondary outcomes

  1. Evaluation of satisfaction

    Evaluation of satisfaction according to the CGI (Clinical Global Impression), at 6 months and 1 year

    Time frame: 6 months and 1 year after surgery

  2. Evaluation of endometriosis-specific pain

    Evaluation of endometriosis-specific pain according to the ENDOPAIN 4D score (which vary from 0 (no pain component) up to 110 (worst pain component)) before randomization and after surgery performed in all cases at 6 months and 1 year.

    Time frame: From randomization to 6 months and 1 year

  3. Evaluation of pain according to a Simple Numerical Scale (NSS)

    Evaluation of their score difference (2) and evaluation of pain according to a Simple Numerical Scale (NSS) ( from 0 (no pain) up to 10 (worst pain) before / after surgery at 6 months and 1 year

    Time frame: 6 months and 1 year after surgery

  4. Improvement of EHP5 score

    Improvement of Endometriosis Health Profile (EHP5) score (from 0 (best quality of life) up to 100 (worst quality of life)) at 6 months and 1 year and difference between the beginning and between the two groups.

    Time frame: 6 months and 1 year after surgery

  5. Assessment of prevalence of complex pain syndrome

    Assessment of prevalence of complex pain syndrome in the whole population included: neuropathic pain (DN4 (from 0 (no symptoms) up to 10 (the most symptoms)) and PainDETECT score (from 0 (no probability of neuropathic pain unlikely) up to 38 (probability of neuropathic pain more likely)), sensitization (peripheral and central with Perineal Pain Sensitization Criteria (PPSC) (from 0 (no criteri) up to 10 (all criteria)) and Central Sensitization Inventory (CSI) score (from 0 ( no component) up to 100 (always and all components), associated catastrophizing (Pain Catastrophizing Score (PCS) (from 0 (no catastrophizing compenent) up to 52 (always and all catastrophizing components).

    Time frame: Baseline

  6. Assessment of determinant of complex pain syndrom of endometriosis

    Assessment of determinants (previous medical conditions, demographical medical data and previous treatment before surgery) of complex pain syndrome of endometriosis (as describe in previous secondary outcome) with statistical modelization.

    Time frame: Baseline

  7. Calculation of the performance of the CSI test

    Calculation of the performance (sensitivity, specificity, prevalence, accuracy) of the CSI test within this population.

    Time frame: Baseline

  8. Calculation of performance of each test and correlation

    Calculation of the performance of each test proposed before randomization (DN4, PainDETECT, PPSC and PCS score) (prevalence) and correlation (kappa correlation) for neuropathic pain (DN4 and PainDETECT).

    Time frame: Baseline

06

Study locations

1 of 9 sites recruiting
  • Bordeaux University Hospital
    Bordeaux, France 33000, France
    Not yet recruiting
  • IFEMENDO
    Bordeaux, France 33000, France
    Not yet recruiting
  • Versailles Hospital
    Le Chesnay, France 78150, France
    • Pierre PANEL · Contact · ppanel@ght78sud.fr · 01 39 63 97 33
    • Pierre PANEL · Principal investigator
    Not yet recruiting
  • Saint-Vincent-de-Paul Hospital
    Lille, France 59000, France
    Not yet recruiting
  • Limoges University hospital
    Limoges, France 87042, France
    Recruiting
  • Poissy-St-Germain Intercommunal hospital center
    Poissy, France 78303, France
    Not yet recruiting
  • Poitiers University Hospital
    Poitiers, France 86000, France
    Not yet recruiting
  • Mutual Clinic La Sagesse
    Rennes, France 33043, France
    Not yet recruiting
  • South Hospital Rennes University Hospital
    Rennes, France 35203, France
    Not yet recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06997809
Lead sponsor
University Hospital, Limoges
Responsible party
Sponsor
First posted
May 30, 2025
Start date
Aug 5, 2026
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Sep 4, 2026

Study contacts

Safirah AKOWANOU
Contact
safirah.akowanou@chu-limoges.fr
+33555058755
Abdeslam BEN TALEB
Contact
abdeslam.bentaleb@chu-limoges.fr
+33555058616
François Dr. Margueritte
principal investigator · University Hospital, Limoges

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion